A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)

开始日期2026-04-24

申办/合作机构

Almirall SA

CTIS2024-519811-32-00

/ Not yet recruiting临床4期

An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

开始日期2026-04-01

申办/合作机构-

NCT07352566

/ Not yet recruiting临床4期IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

开始日期2026-01-01

申办/合作机构

The University of California, San Francisco

100 项与来金珠单抗相关的临床结果

登录后查看更多信息

100 项与来金珠单抗相关的转化医学

登录后查看更多信息

100 项与来金珠单抗相关的专利（医药）

登录后查看更多信息

233

项与来金珠单抗相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

作者: Yang, Xuefan ; Ruan, Dandan ; Chen, Xiang ; Li, Sitong ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

2026-03-02·Dermatitis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review.

Review

作者: Mehta, Apoorva ; Guttman-Yassky, Emma ; O'Hagan, Ross ; Lamb, Angela J ; Levine, Jasmine

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. In recent years, treatment has advanced from broad immunosuppressants to targeted biologics and small-molecule therapies that modulate type 2 inflammation and itch signaling. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Comparative trials highlight faster itch relief with JAKis but durable disease control and safety advantages with biologics. The expanding treatment landscape necessitates individualized therapy selection. Key clinical considerations include patient age, pregnancy status, infection, malignancy, or thromboembolic risk, comorbid conditions, and history of adverse effects. Equally important are patient-centered preferences such as dosing frequency, route of administration, storage logistics, and willingness to self-inject. Access and affordability also influence care, with many manufacturers offering copay support and patient assistance programs. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities.

2026-03-01·JOURNAL OF DERMATOLOGY

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long‐Term Treatment With Dupilumab: A Single‐Center Retrospective Study

Letter

作者: Chijiwa, Chika ; Okada, Yoshiki ; Tada, Yayoi ; Suzuki, Shoya ; Hiura, Azusa ; Kamata, Masahiro ; Tomura, Yayoi ; Hayashi, Kotaro ; Watanabe, Ayu ; Tanaka, Takamitsu

507

项与来金珠单抗相关的新闻（医药）

2026-03-27
·动脉网

礼来公司的EBGLYSS（lebrikizumab-lbkz）为中重度特应性皮炎患者提供了长达四年的持久疾病控制Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement ( 在ADlong第三阶段b研究中，几乎所有接受EBGLYSS治疗的患者都实现了显著的皮肤改善 (EASI 易学易用-75) for up to four years -75）最长四年75% of patients achieved a high bar of near-complete skin clearance ( 75%的患者达到了接近完全皮肤清除的高标准（EASI 易学易用-90) and 78% experienced significant itch relief (Pruritus NRS -90）并且78%的患者获得了显著的瘙痒缓解（Pruritus NRS≤ ≤4), one of the most bothersome symptoms for patients 4)，患者最烦人的症状之一80% of patients achieved durable results without the need for topical corticosteroids 80%的患者在无需使用局部皮质类固醇的情况下获得了持久的效果。INDIANAPOLIS 印第安纳波利斯, ，March 27, 2026 2026年3月27日/PRNewswire/ -- New long-term data show /PRNewswire/ -- 新的长期数据显示Eli Lilly and Company's 礼来公司(NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the . （纽约证券交易所代码：LLY）EBGLYSS（lebrikizumab-lbkz）在一项开放标签扩展研究中，为中度至重度特应性皮炎（湿疹）患者提供了长达四年的持久皮肤清除和持续瘙痒缓解，该研究提供每月一次的维持注射。ADlong 第3b期研究第一年的中期结果将在会议上公布。American Academy of Dermatology 美国皮肤病学会(AAD) Annual Meeting, taking place (AAD) 年会，正在举行March 27-31 3月27日至31日 in 在Denver 丹佛. 。1 1'These data underscore our unwavering commitment to expanding what people with moderate-to-severe atopic dermatitis can achieve with treatment,' said “这些数据强调了我们对扩大中度至重度特应性皮炎患者通过治疗所能实现的目标的坚定承诺，”Adrienne Brown 阿德里安·布朗, executive vice president and president, Lilly Immunology. 'For too long the focus has been around symptom management and many patients struggle to achieve consistent disease control despite cycling through topical treatments. EBGLYSS is helping transform this treatment paradigm—allowing people the opportunity to reimagine life without the frequent interruptions caused by flares or topicals applied 2-3 times per day.'. ，执行副总裁兼礼来免疫学总裁。“长期以来，重点一直放在症状管理上，尽管患者不断尝试局部治疗，但许多患者仍难以实现持续的疾病控制。EBGLYSS 正在帮助转变这种治疗模式——让人们有机会重新构想没有因病情发作或每天 2-3 次局部用药带来的频繁干扰的生活。”EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate. EBGLYSS是一种白细胞介素-13（IL-13）抑制剂，能够以高结合亲和力和缓慢的解离速率选择性阻断IL-13信号传导。2,3,4 2,3,4The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection. 细胞因子IL-13是特应性皮炎的主要细胞因子，驱动皮肤中的2型炎症循环，导致皮肤屏障功能障碍、瘙痒、皮肤增厚和感染。5,6 5,6In the ADlong study, the majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients (77%) were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study.. 在ADlong研究中，大多数患者在接受长达四年的连续EBGLYSS治疗后，达到了接近完全的皮肤清除和显著的瘙痒缓解。大多数患者（77%）仅接受EBGLYSS单药治疗，80%的患者在没有使用局部皮质类固醇的情况下取得了效果。此外，在研究期间，80%的患者通过每月一次的EBGLYSS维持剂量达成了这些成果。Efficacy results at up to four years of continuous treatment* 长达四年的连续治疗的有效性结果*EASI 易学易用-75** -75**94% 94%EASI 易学易用-90 -90† †75% 75%IGA 0,1 IGA 0.1‡ ‡68% 68 %Pruritus NRS ≤4 瘙痒 NRS ≤4§ §78% 78 %* Data are reported as observed * 数据按实际观测值报告** **EASI 易学易用=Eczema Area and Severity Index; 湿疹面积和严重程度指数；EASI 易学易用-75=75% reduction in -75=减少75%EASI 易学易用from baseline 从基线† †EASI 易学易用-90=90% reduction in -90=减少90%EASI 易学易用from baseline 从基线‡ IGA 0,1=Investigator's Global Assessment 0 or 1 ('clear' or 'almost clear') ‡ IGA 0,1=研究者整体评估 0 或 1（“清除”或“几乎清除”）§ Pruritus NRS=Numeric Rating Scale rating itch from 0-10 with 10 being worst imaginable itch within the past 24 hours § 瘙痒 NRS=数字评分量表，过去24小时内从0-10评分瘙痒程度，10为可想象的最严重瘙痒The safety of EBGLYSS in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation. 在ADlong研究的第一年中，EBGLYSS的安全性与已知的中重度特应性皮炎患者中的表现一致，且不依赖于剂量频率，未观察到新的安全性信号。大多数不良事件为轻度或中度，并未导致停药。Reported treatment-related adverse events in the study included conjunctivitis (6.9%) and injection-site reactions (0.6%).. 研究中报告的与治疗相关的不良事件包括结膜炎 (6.9%) 和注射部位反应 (0.6%)。The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce ADlong 研究正在进行中，并将持续进行额外一年的治疗。这些结果进一步证实了previously reported long-term results 以前报告的长期结果for EBGLYSS for patients with moderate-to-severe atopic dermatitis. In addition, a post-hoc analysis presented at Maui Derm Hawaii 2026 on 针对中重度特应性皮炎患者的EBGLYSS。此外，一项在2026年毛伊岛皮肤科会议上展示的事后分析表明，EASI 易学易用-75 stable responders showed less than one flare per patient per year with EBGLYSS monthly maintenance dosing used as monotherapy. -75名稳定应答者在使用EBGLYSS每月维持剂量作为单一疗法时，每年每名患者的病情复发少于一次。7 7'There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch,' said “对于中度至重度特应性皮炎患者，仍然存在未满足的需求，他们经常经历不可预测的病情发作，需要的治疗方案不仅要缓解症状，还要针对引发皮肤症状和持续瘙痒的根本炎症。”Emma Guttman-Yassky 艾玛·古特曼-亚萨基, M.D., Ph.D., The Waldman Professor and Health System Chair, 医学博士、哲学博士，沃尔德曼教授兼卫生系统主席，Department of Dermatology 皮肤病学系at the 在Icahn School of Medicine at Mount Sinai 西奈山伊坎医学院 in 在New York 纽约. 'These four-year findings reinforce thatEBGLYSS has the potential to deliver durable disease control, helping patients flare less with or without topicals.' “这四项为期四年的研究结果进一步证实，EBGLYSS 有潜力提供持久的疾病控制，帮助患者减少使用或不使用外用药时的病情发作。”Lilly continues to raise the standard of care in dermatology and boldly invest in the next wave of immunology innovation, which includes big bets on next-generation modalities, the targeted expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsA and TOGETHER-PsO trials investigating the concomitant use of ixekizumab and an incretin-based therapy to treat adults with psoriatic disease and obesity or overweight with at least one additional weight-related comorbid condition. 礼来继续提高皮肤病学的护理标准，并大胆投资于下一波免疫学创新，其中包括对下一代治疗模式的大胆押注、小分子的有针对性扩展以及推进揭示肠促胰岛素潜力的新科学。礼来最近分享了TOGETHER-PsA和TOGETHER-PsO试验的顶线结果，这些试验研究了ixekizumab与基于肠促胰岛素的疗法联合使用，以治疗患有银屑病和肥胖或超重且至少有一种其他与体重相关的合并症的成人患者。Lilly's investigational therapies include DC-853, a novel oral IL-17 inhibitor being studied for psoriasis, and eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation and is being assessed in hidradenitis suppurativa.. 礼来公司的在研疗法包括DC-853，一种正在研究用于治疗银屑病的新型口服IL-17抑制剂，以及eltrekibart，一种靶向中性粒细胞驱动炎症的新型单克隆抗体，正在被评估用于化脓性汗腺炎。Lilly has exclusive rights for development and commercialization of EBGLYSS in the 礼来公司拥有 EBGLYSS 的独家开发和商业化权利。U.S. 美国and the rest of the world outside 而外界的其他地方Europe 欧洲. Lilly's partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in 礼来公司的合作伙伴阿尔米拉尔已获得开发和商业化EBGLYSS用于治疗皮肤病适应症（包括特应性皮炎）的权利许可。Europe 欧洲. 。About ADlong 关于ADlongADlong ( AD长（NCT05916365 NCT05916365) open-label extension study is evaluating the long-term safety and efficacy of EBGLYSS 250 mg dosed every four weeks (Q4W) in patients with moderate-to-severe atopic dermatitis for a total of 108 weeks. Adult and adolescent (ages 12–17, weighing ≥40 kg) patients from select countries in ）开放标签扩展研究正在评估EBGLYSS 250 mg每四周一次（Q4W）在中度至重度特应性皮炎患者中的长期安全性和有效性，总疗程为108周。来自选定国家的成人和青少年（12-17岁，体重≥40公斤）患者参与了此项研究。Europe 欧洲who completed the 100-week ADjoin extension study, including patients who completed the ADore trial (52 weeks), the ADhere trial (16 weeks), and Week 16 responders who completed theADvocate 1 and 2 trials (52 weeks), were eligible to enroll in ADlong. Patients (N=174) in this analysis receive open-label EBGLYSS 250 mg Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose). 完成了为期100周的ADjoin扩展研究的患者，包括完成ADore试验（52周）、ADhere试验（16周）以及完成ADvocate 1和2试验（52周）的第16周应答者，均有资格注册参与ADlong。本分析中的患者（N=174）接受开放标签的EBGLYSS 250 mg Q4W治疗，无论他们之前在ADjoin中的治疗方案是Q2W还是Q4W剂量。The approved maintenance dose of EBGLYSS is 250 mg once monthly, after taking EBGLYSS every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response).. EBGLYSS 的批准维持剂量为每月一次 250 毫克，在最初的四个月初始剂量阶段（或在达到足够的临床反应后）每两周服用 EBGLYSS。8 8Intermittent use of topical rescue medications and short-term systemic treatments was allowed. 允许间歇性使用局部急救药物和短期系统治疗。1 1If response was below 如果响应低于EASI 易学易用-50, Q2W could be used and thereafter Q4W could be resumed. -50，可以使用Q2W，之后可以恢复Q4W。About EBGLYSS 关于EBGLYSSEBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate. EBGLYSS是一种单克隆抗体，能够以高亲和力和缓慢的解离速度选择性地靶向并中和IL-13。3,4,8 3，4，8EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.. EBGLYSS结合到IL-13细胞因子的一个区域，该区域与IL-13Rα1/IL-4Rα异二聚体中IL-4Rα亚基的结合位点重叠，阻止该受体复合物的形成并抑制IL-13信号传导。IL-13被认为是一种与湿疹病理生理学相关的主要细胞因子，可驱动皮肤中的2型炎症循环，而EBGLYSS选择性靶向IL-13。8 8The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating over 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin), adolescent open-label (ADore) and pediatric (ADorable 1 and 2) studies. EBGLYSS在特应性皮炎的第三阶段项目包括七项关键的全球研究，评估了超过1600名患者，其中包括两项单药治疗研究（ADvocate 1和2）、一项与局部皮质类固醇联合使用的研究（ADhere）、长期扩展研究（ADjoin）、青少年开放标签研究（ADore）以及儿科研究（ADorable 1和2）。EBGLYSS is also being studied in allergic rhinitis and chronic rhinosinusitis with nasal polyps.. EBGLYSS 还在过敏性鼻炎和伴鼻息肉的慢性鼻窦炎中进行研究。EBGLYSS was approved in the EBGLYSS 已获批U.S. 美国, ，Japan 日本and 和Canada 加拿大in 2024 and in the 2024年以及在European Union 欧盟in 2023. EBGLYSS is a first-line biologic treatment with the option of monotherapy that offers once-monthly maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.. 在2023年。EBGLYSS 是一种一线生物治疗，可选择单药治疗，每月一次维持剂量，适用于12岁及以上、体重至少88磅（40公斤）、中度至重度特应性皮炎且局部处方疗法控制不佳的成人和儿童。8 8EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks) which can be used with or without topical corticosteroids.. EBGLYSS 250 mg/2 mL 注射剂在初始治疗阶段后，作为单次每月维持注射使用。EBGLYSS 的推荐初始剂量为第 0 周和第 2 周时每次 500 mg（两次 250 mg 注射），随后每两周注射 250 mg，直至第 16 周或更晚达到充分临床反应；此后，维持剂量为每月一次单次注射（每四周 250 mg），可与局部皮质类固醇联合使用或单独使用。8 8Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans. 礼来致力于为中重度特应性皮炎患者服务，并通过商业保险为那些使用局部处方治疗效果不佳的患者提供广泛的一线生物药物EBGLYSS的获取渠道。礼来已与三大全国性药房福利管理公司全面覆盖，94%的商业保险患者通过国家健康计划获得保障。We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative.Through Lilly Support Services, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients.. 我们已经扩大了医疗补助覆盖范围，并且作为礼来公司健康公平与可负担性计划的一部分，我们正在追求同样广泛的医疗保险覆盖。通过礼来支持服务，礼来为符合条件的、商业保险的患者提供包括共付援助在内的患者支持计划。INDICATION AND SAFETY SUMMARY 适应症与安全概述 EBGLYSS EBGLYSS® ®(EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. (EHB-glihs) 是一种注射药物，用于治疗 12 岁及以上、体重至少 88 磅（40 公斤）的中度至重度湿疹（特应性皮炎）成人和儿童患者，这些患者的病情通过局部（皮肤上使用的）处方疗法无法得到良好控制，或者无法使用局部疗法。EBGLYSS can be used with or without topical corticosteroids.. EBGLYSS 可以与局部皮质类固醇一起使用，也可以单独使用。It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg). 在年龄小于12岁的儿童或体重小于88磅（40公斤）的12岁至未满18岁儿童中，尚不清楚EBGLYSS是否安全有效。 Warnings - Do not use 警告 - 不要使用EBGLYSS EBGLYSSif you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients. 如果您对莱布立珠单抗-lbkz或EBGLYSS中的任何成分过敏。请参阅随EBGLYSS提供的患者信息说明书，以获取完整的成分列表。Before using 使用前Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you: 在使用 EBGLYSS 之前，请告诉您的医疗保健提供者您的所有健康状况，包括您是否：Have a parasitic (helminth) infection. 患有寄生虫（蠕虫）感染。Are scheduled to receive any vaccinations. You should not receive a 'live vaccine' if you are treated with EBGLYSS. 计划接种任何疫苗。如果您正在使用EBGLYSS进行治疗，则不应接种“活疫苗”。Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call 怀孕或计划怀孕。目前尚不清楚EBGLYSS是否会伤害您未出生的宝宝。如果您在使用EBGLYSS治疗期间怀孕，您或您的医疗保健提供者可以致电Eli Lilly and Company 礼来公司at 1-800-LillyRx (1-800-545-5979) to report the pregnancy. 拨打1-800-LillyRx（1-800-545-5979）报告怀孕情况。Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk. 正在哺乳或计划哺乳。目前尚不清楚EBGLYSS是否会进入您的母乳中。 Tell your healthcare provider about all the medicines you take 告诉您的医疗保健提供者您所服用的所有药物, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ，包括处方药和非处方药、维生素以及草本补充剂。Possible side effects 可能的副作用EBGLYSS can cause serious side effects, including: EBGLYSS可能会引起严重的副作用，包括：Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. 过敏反应。EBGLYSS 可能会引起有时可能很严重的过敏反应。Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: 如果出现以下任何症状，请立即停止使用EBGLYSS，并告知您的医疗保健提供者或寻求紧急帮助：breathing problems or wheezing 呼吸困难或喘息swelling of the face, lips, mouth, tongue or throat 面部、嘴唇、口腔、舌头或喉咙肿胀hives 蜂巢itching 瘙痒fainting, dizziness, feeling lightheaded 昏厥、头晕、感觉头重脚轻skin rash 皮疹cramps in your stomach area (abdomen) 腹部（腹腔）绞痛Eye problems. 眼部问题。Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. 如果您有任何新的或恶化的眼部问题，包括眼痛或视力变化（如视力模糊），请告知您的医疗保健提供者。The most common side effects of EBGLYSS include: EBGLYSS最常见的副作用包括：eye and eyelid inflammation, including redness, swelling, and itching 眼睛和眼睑炎症，包括发红、肿胀和瘙痒injection site reactions 注射部位反应shingles (herpes zoster) 带状疱疹These are not all of the possible side effects of EBGLYSS. 这些并非 EBGLYSS 的所有可能副作用。Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or 如需了解有关副作用的医疗建议，请咨询您的医生。您可以致电1-800-FDA-1088向FDA报告副作用，或者www.fda.gov/medwatch www.fda.gov/medwatch. 。How to take 如何服用See the detailed 'Instructions for Use' that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes. 请参阅随 EBGLYSS 一起提供的详细“使用说明”，了解如何准备和注射 EBGLYSS，以及如何正确存放和丢弃（处理）已使用的 EBGLYSS 预填充笔和预填充注射器。Use EBGLYSS exactly as prescribed by your healthcare provider. 请严格按照您的医疗保健提供者的处方使用EBGLYSS。EBGLYSS is given as an injection under the skin (subcutaneous injection). EBGLYSS 通过皮下注射给药。If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver.. 如果您的医疗保健提供者决定您或护理人员可以注射EBGLYSS，则您或护理人员应接受关于正确准备和注射EBGLYSS的培训。在您的医疗保健提供者向您展示正确方法之前，请勿尝试注射EBGLYSS。对于12岁及以上的儿童，EBGLYSS应由护理人员给予。If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time. 如果您错过了注射EBGLYSS，尽快补注射错过的剂量，然后在常规预定时间注射下一剂。Learn more 了解更多EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call EBGLYSS 是一种处方药，有 250 毫克/2 毫升注射预填充笔或预填充注射器两种形式。欲了解更多信息，请拨打1-800-545-5979 1-800-545-5979or go to 或前往ebglyss.lilly.com ebglyss.lilly.comThis summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. 本摘要提供了有关 EBGLYSS 的基本信息，但并未包含有关此药物的所有信息。每次配药时，请务必阅读随处方提供的信息。此信息不能代替与医生的沟通。务必与您的医生或其他医疗保健提供者讨论 EBGLYSS 及其用法。Your doctor is the best person to help you decide if EBGLYSS is right for you.. 您的医生是帮助您确定 EBGLYSS 是否适合您的最佳人选。LK CON BS LK CON BSAD APP 广告应用EBGLYSS®, its delivery device base, and Lilly Support Services™ are trademarks owned or licensed by EBGLYSS®、其输送装置底座和Lilly Support Services™ 是由Eli Lilly and Company 礼来公司, its subsidiaries, or affiliates. ，其子公司或附属公司。About Lilly 关于LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. 礼来是一家医药公司，将科学转化为治疗手段，致力于改善世界各地人们的生活。近150年来，我们一直是改变生命的发现的先驱，如今我们的药物正在帮助全球各地的人们。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转变为可管理的疾病。With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit. 每迈向更健康的世界一步，我们都受到一个目标的激励：让数百万人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药物可及且负担得起。欲了解更多信息，请访问。Lilly.com 莉莉网and 和Lilly.com/news Lilly.com/新闻, or follow us on ，或者关注我们Facebook 脸书, ，Instagram Instagramand 和LinkedIn 领英. P-LLY . P-LLYTrademarks and 商标和Trade Names 商标名称All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. 本新闻稿中提到的所有商标或商号均为公司财产，或者，若涉及属于其他公司的商标或商号，则为其各自所有者的财产。仅为方便起见，本新闻稿中提及的商标和商号未附带®和™符号，但此类引用不应被解释为表明公司或在适用情况下其各自所有者不会根据适用法律最大限度地主张公司或其对该等权利的所有权。We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.. 我们无意通过使用或展示其他公司的商标和商号来暗示我们与其他公司存在关联，或受到其他公司的认可或赞助。Cautionary Statement Regarding Forward-Looking Statements 关于前瞻性陈述的警示声明This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about EBGLYSS (lebrikizumab-lbkz) as a treatment for patients with moderate-to severe atopic dermatitis and the timeline for future readouts, presentations, and other milestones relating to EBGLYSS and its clinical trials and reflects Lilly'scurrent beliefs and expectations. 本新闻稿包含前瞻性声明（该术语定义见1995年《私人证券诉讼改革法案》），涉及EBGLYSS（lebrikizumab-lbkz）作为中至重度特应性皮炎患者的治疗方案，以及与EBGLYSS及其临床试验相关的未来数据发布、展示和其他里程碑的时间表，反映了礼来公司当前的信念和预期。However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date or that EBGLYSS will receive additional regulatory approvals, or that it will be commercially successful. 然而，与任何医药产品一样，药物的研发和商业化过程中存在重大风险和不确定性。其中，不能保证未来的研究结果会与迄今为止的结果一致，也不能保证EBGLYSS会获得更多的监管批准，或者它会在商业上取得成功。For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the . 有关这些可能导致实际结果与礼来公司预期不同的风险和其他不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的Form 10-K和Form 10-Q报告。United States Securities and Exchange Commission 美国证券交易委员会. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. 除非法律要求，礼来公司没有义务更新前瞻性声明以反映本发布日期之后的事件。1 1Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. Weidinger S.等人。Lebrikizumab在中度至重度特应性皮炎患者中的疗效和安全性可维持长达4年：ADlong长期扩展试验的第一年。American Academy of Dermatology 美国皮肤病学会Annual Meeting. 年度会议。March 2026 2026年3月2 2Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017. 辛普森 EL 等。Lebrikizumab（一种抗IL-13单克隆抗体）在局部皮质类固醇控制不佳的中重度特应性皮炎成人患者中的疗效与安全性：一项随机、安慰剂对照的II期试验（TREBLE）。《美国皮肤病学会杂志》。2018；78（5）：863-871.e11。doi:10.1016/j.jaad.2018.01.017。3 3Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7 Okragly A, 等。白细胞介素-13抗体Lebrikizumab的结合、中和与内化。《皮肤病治疗学》（海德堡）。2023；13(7):1535-1547。doi:10.1007/s13555-023-00947-74 4Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024 乌尔奇 M 等。抗IL-13抗体Lebrikizumab对信号阻断的结构基础。《分子生物学杂志》。2013；425（8）：1330-1339。doi:10.10116/j.jmb.2013.01.0245 5Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954 比伯 T. 白细胞介素-13：在特应性皮炎中针对一种被低估的细胞因子。《过敏》。2020；75（1）：54-62。doi:10.1111/all.139546 6Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018 崔LC等。特应性皮炎是一种以IL-13为主的疾病，与银屑病相比具有更大的分子异质性。《皮肤病学研究杂志》。2019;139(7):1480-1489。doi:10.1016/j.jid.2018.12.0187 7Merola J, et al. Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term Study: A Post-hoc Analysis of the ADjoin Study. Maui Derm Hawaii. Merola J, 等。在长期研究中，对莱布立珠单抗有稳定反应的特应性皮炎患者复发较少：ADjoin研究的事后分析。毛伊岛皮肤科夏威夷。January 2026 2026年1月8 8EBGLYSS. Prescribing Information. EBGLYSS。处方信息。Lilly USA, LLC 美国礼来公司. 。Refer to: 参考：Kelly Hoffman; 凯莉·霍夫曼；kelly.hoffman@lilly.com 凯莉·霍夫曼@礼来公司.com; 765-736-2555 (Lilly media) ；765-736-2555（礼来媒体）MichaelCzapar; 迈克尔·查帕尔；czapar_michael_c@lilly.com czapar_michael_c@lilly.com; 317-617-0983 (Investors) ；317-617-0983（投资者）View original content to download multimedia: 查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/lillys-ebglyss-lebrikizumab-lbkz-delivered-up-to-four-years-of-durable-disease-control-for-patients-with-moderate-to-severe-atopic-dermatitis-302727205.html https://www.prnewswire.com/news-releases/lillys-ebglyss-lebrikizumab-lbkz-为中度至重度特应性皮炎患者提供了长达四年的持久疾病控制-302727205.htmlSOURCE 源代码Eli Lilly and Company 礼来公司

临床结果临床2期临床研究

2026-03-27
·Business Wire

Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study*, 94% of patients achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment, reinforcing the sustained response achieved over time in patients with moderate-to-severe atopic dermatitis 1 . 75% of patients achieved near-complete skin clearance (EASI-90) and 78% experienced meaningful itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients. At AAD, Almirall and its partners also presented more than 15 posters across atopic dermatitis, psoriasis, actinic keratosis and acne, strengthening its commitment to improving patient outcomes and aligned with its leadership in medical dermatology. BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today presented positive long-term interim results from the ongoing Phase 3b ADlong study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD). Lebrikizumab delivered near-complete skin clearance and itch relief for up to four years for patients with moderate-to-severe atopic dermatitis, while maintaining its established safety profile. Interim findings from the first year of the ADlong Phase 3b study were presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver2. “At Almirall, we are committed to advancing skin science with meaningful therapies that improve patients’ lives. These interim data from the ADlong study further support the long-term value of lebrikizumab in treating patients with moderate-to-severe atopic dermatitis, highlighting its potential to fundamentally improve disease control and positively transform patients’ quality of life,” said Karl Ziegelbauer, Chief Scientific Officer at Almirall. “Long-term efficacy is essential in moderate-to-severe atopic dermatitis, a disease characterized by chronic inflammation and unpredictable flares. When a treatment can offer patients sustained control of both skin symptoms and itch over several years, it has the potential to transform daily life and redefine what we consider achievable in AD management,” said Prof Weidinger, University Medical Center Schleswig-Holstein, Department for Dermatology and Allergy. In the ADlong study, the majority of patients achieved near-complete skin clearance and clinically meaningful itch relief with up to four years of continuous lebrikizumab treatment. Most patients (77%) were on lebrikizumab monotherapy, and the majority of patients (80%) achieved these results without topical corticosteroids. In addition, 80% achieved these outcomes with lebrikizumab monthly maintenance dosing during the study. Efficacy results at week 48 of ADlong, up to four years of continuous treatment EASI-75** 94% EASI-90† 75% IGA 0,1‡ 68% Pruritus NRS ≤4§ 78% *Data are reported as observed ** EASI=Eczema Area and Severity Index; EASI-75=75% reduction in EASI from baseline † EASI-90=90% reduction in EASI from baseline ‡ IGA 0,1=Investigator's Global Assessment 0 or 1 ("clear" or "almost clear") § Pruritus NRS=Numeric Rating Scale rating itch from 0-10 with 10 being worst imaginable itch within the past 24 hours The safety of lebrikizumab in this first year of the ADlong study was consistent with the established safety profile in patients with moderate-to-severe atopic dermatitis, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation. Reported treatment-related adverse events in the study included nasopharyngitis, URTI and conjunctivitis. The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce the sustained response achieved with lebrikizumab over time in patients with moderate-to-severe atopic dermatitis3, building on recently published findings showing that continued treatment for two years enabled a substantial proportion of responder population (41%) to achieve complete skin clearance and itch relief4. At AAD, Almirall and its partners shared new data and more than 15 posters across atopic dermatitis, psoriasis, actinic keratosis and acne, reinforcing its commitment to improving patient outcomes through advancing science and a diverse portfolio that uses novel modalities to address debilitating conditions such as hidradenitis suppurativa, alopecia areata, and atopic dermatitis. About ADlong ADlong (NCT05916365) open-label extension study is evaluating the long-term safety and efficacy of lebrikizumab 250 mg dosed every four weeks (Q4W) in patients with moderate-to-severe atopic dermatitis for a total of 108 weeks. Adult and adolescent patients (ages 12–17, weighing ≥40 kg) from Germany and Poland who completed the 100-week ADjoin extension study, including responders from the ADvocate 1 and 2 trials (52 weeks), ADore trial (52 weeks) and the ADhere (16 weeks) trial, were eligible to enroll in ADlong. Patients (N=174) in this analysis receive open-label lebrikizumab 250 mg Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose). The approved maintenance dose of lebrikizumab is 250 mg once monthly, after taking lebrikizumab every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response)5. Intermittent use of topical rescue medications and short-term systemic treatments was allowed6. If response was below EASI50, Q2W could be used and thereafter Q4W could be resumed. About Lebrikizumab Lebrikizumab (LEB) is a monoclonal antibody that selectively targets the cytokine IL-13 with high affinity, blocking its downstream signaling7,8,9,10,11, while avoiding broader immunosuppression12,13 and preserving IL-13 physiological clearance14. Lebrikizumab is approved in Europe, under the brand name Ebglyss®, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy15. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe, while Eli Lilly and Company retains rights for development and commercialization in the U.S. and the rest of the world outside Europe. About Almirall Almirall is a global biopharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs. Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2025: €1114.5 MM, over 2100 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries. Legal warning This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law. *These results are interim findings from the first year of the ADlong Phase 3b study and will be publicly disclosed at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31, 2026, in Denver (US) 1 Thaçi, et al. Late breaking news EADV 2024, D1T01.2 2 Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. American Academy of Dermatology Annual Meeting. March 2026 3 Thaçi, et al. Late breaking news EADV 2024, D1T01.2 4 Simpson E, Biedermann T, Kircik L, et al. Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years. J Dermatolog Treat. 2026;37(1):2631233. doi:10.1080/09546634.2026.2631233 5 European Medicines Agency (EMA). Ebglyss: EPAR—Product Information. Accessed February 7, 2026. 6 Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. American Academy of Dermatology Annual Meeting. March 2026 7 Moyle M, Cevikbas F, Harden JL, Guttman‑Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756‑768. 8 Okragly AJ, Ryuzoji A, Wulur I, Daniels M, Van Horn RD, Patel CN, et al. Binding, neutralization and internalization of the interleukin‑13 antibody, lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535‑1547. 9 Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti‑IL‑13 antibody lebrikizumab. J Mol Biol. 2013;425(8):1330‑1339. 10 Tsuji G, Yamamura K, Kawamura K, Kido‑Nakahara M, Ito T, Nakahara T. Novel therapeutic targets for the treatment of atopic dermatitis. Biomedicines. 2023;11:1303. 11 Furue M, Ulzii D, Nakahara T, Tsuji G, Furue K, Hashimoto‑Hachiya A, et al. Implications of IL‑13Rα2 in atopic skin inflammation. Allergol Int. 2020;69:412‑416. 12 Moyle M, Cevikbas F, Harden JL, Guttman‑Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756‑768. 13 Gonçalves F, Freitas E, Torres T. Selective IL‑13 inhibitors for the treatment of atopic dermatitis. Drugs Context. 2021;10:2021‑1‑7. doi:10.7573/dic.2021‑1‑7. 14 Moyle M, Cevikbas F, Harden JL, Guttman‑Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756‑768. 15 European Medicines Agency (EMA). Ebglyss: EPAR—Product Information. Accessed February 7, 2026. https://www.ema.europa.eu/en/documents/product-information/ebglyss-epar-product-information_en.pdf

临床结果临床3期上市批准

2026-03-27
·PRNewswire

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78% experienced significant itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients 80% of patients achieved durable results without the need for topical corticosteroids INDIANAPOLIS, March 27, 2026 /PRNewswire/ -- New long-term data show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1 "These data underscore our unwavering commitment to expanding what people with moderate-to-severe atopic dermatitis can achieve with treatment," said Adrienne Brown, executive vice president and president, Lilly Immunology. "For too long the focus has been around symptom management and many patients struggle to achieve consistent disease control despite cycling through topical treatments. EBGLYSS is helping transform this treatment paradigm—allowing people the opportunity to reimagine life without the frequent interruptions caused by flares or topicals applied 2-3 times per day." EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate.2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6 In the ADlong study, the majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients (77%) were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study. * Data are reported as observed ** EASI=Eczema Area and Severity Index; EASI-75=75% reduction in EASI from baseline † EASI-90=90% reduction in EASI from baseline ‡ IGA 0,1=Investigator's Global Assessment 0 or 1 ("clear" or "almost clear") § Pruritus NRS=Numeric Rating Scale rating itch from 0-10 with 10 being worst imaginable itch within the past 24 hours The safety of EBGLYSS in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation. Reported treatment-related adverse events in the study included conjunctivitis (6.9%) and injection-site reactions (0.6%). The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce previously reported long-term results for EBGLYSS for patients with moderate-to-severe atopic dermatitis. In addition, a post-hoc analysis presented at Maui Derm Hawaii 2026 on EASI-75 stable responders showed less than one flare per patient per year with EBGLYSS monthly maintenance dosing used as monotherapy.7 "There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch," said Emma Guttman-Yassky, M.D., Ph.D., The Waldman Professor and Health System Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York. "These four-year findings reinforce that EBGLYSS has the potential to deliver durable disease control, helping patients flare less with or without topicals." Lilly continues to raise the standard of care in dermatology and boldly invest in the next wave of immunology innovation, which includes big bets on next-generation modalities, the targeted expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsA and TOGETHER-PsO trials investigating the concomitant use of ixekizumab and an incretin-based therapy to treat adults with psoriatic disease and obesity or overweight with at least one additional weight-related comorbid condition. Lilly's investigational therapies include DC-853, a novel oral IL-17 inhibitor being studied for psoriasis, and eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation and is being assessed in hidradenitis suppurativa. Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe. About ADlong ADlong (NCT05916365) open-label extension study is evaluating the long-term safety and efficacy of EBGLYSS 250 mg dosed every four weeks (Q4W) in patients with moderate-to-severe atopic dermatitis for a total of 108 weeks. Adult and adolescent (ages 12–17, weighing ≥40 kg) patients from select countries in Europe who completed the 100-week ADjoin extension study, including patients who completed the ADore trial (52 weeks), the ADhere trial (16 weeks), and Week 16 responders who completed the ADvocate 1 and 2 trials (52 weeks), were eligible to enroll in ADlong. Patients (N=174) in this analysis receive open-label EBGLYSS 250 mg Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose). The approved maintenance dose of EBGLYSS is 250 mg once monthly, after taking EBGLYSS every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response).8 Intermittent use of topical rescue medications and short-term systemic treatments was allowed.1 If response was below EASI-50, Q2W could be used and thereafter Q4W could be resumed. About EBGLYSS EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.3,4,8 EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.8 The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating over 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin), adolescent open-label (ADore) and pediatric (ADorable 1 and 2) studies. EBGLYSS is also being studied in allergic rhinitis and chronic rhinosinusitis with nasal polyps. EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment with the option of monotherapy that offers once-monthly maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.8 EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks) which can be used with or without topical corticosteroids.8 Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans. We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative. Through Lilly Support Services, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients. INDICATION AND SAFETY SUMMARY EBGLYSS ® (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids. It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg). Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients. Before using Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you: Have a parasitic (helminth) infection. Are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with EBGLYSS. Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy. Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Possible side effects EBGLYSS can cause serious side effects, including: Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing swelling of the face, lips, mouth, tongue or throat hives itching fainting, dizziness, feeling lightheaded skin rash cramps in your stomach area (abdomen) Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. The most common side effects of EBGLYSS include: eye and eyelid inflammation, including redness, swelling, and itching injection site reactions shingles (herpes zoster) These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or . How to take See the detailed "Instructions for Use" that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes. Use EBGLYSS exactly as prescribed by your healthcare provider. EBGLYSS is given as an injection under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver. If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time. Learn more EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you. LK CON BS AD APP EBGLYSS®, its delivery device base, and Lilly Support Services™ are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking Statements  This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about EBGLYSS (lebrikizumab-lbkz) as a treatment for patients with moderate-to severe atopic dermatitis and the timeline for future readouts, presentations, and other milestones relating to EBGLYSS and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date or that EBGLYSS will receive additional regulatory approvals, or that it will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. 1 Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. American Academy of Dermatology Annual Meeting. March 2026 2 Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017 3 Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7 4 Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024 5 Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954 6 Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018 7 Merola J, et al. Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term Study: A Post-hoc Analysis of the ADjoin Study. Maui Derm Hawaii. January 2026 8 EBGLYSS. Prescribing Information. Lilly USA, LLC. SOURCE Eli Lilly and Company 21% more press release views with Request a Demo

临床结果临床3期临床2期上市批准

100 项与来金珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09633	来金珠单抗	-	DB11914

研发状态

批准上市

10 条最早获批的记录,
登录
后查看更多信息

适应症	国家/地区	公司	日期
特应性皮炎	欧盟	Almirall SA	2023-11-16
特应性皮炎	冰岛	Almirall SA	2023-11-16
特应性皮炎	列支敦士登	Almirall SA	2023-11-16
特应性皮炎	挪威	Almirall SA	2023-11-16

未上市

10 条进展最快的记录,
登录
后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
钱币状湿疹	临床3期	德国	Almirall SA	2026-04-24
钱币状湿疹	临床3期	意大利	Almirall SA	2026-04-24
钱币状湿疹	临床3期	波兰	Almirall SA	2026-04-24
钱币状湿疹	临床3期	西班牙	Almirall SA	2026-04-24
鼻息肉	临床3期	美国	Eli Lilly & Co.	2024-10-21
鼻息肉	临床3期	中国	Eli Lilly & Co.	2024-10-21
鼻息肉	临床3期	日本	Eli Lilly & Co.	2024-10-21
鼻息肉	临床3期	阿根廷	Eli Lilly & Co.	2024-10-21
鼻息肉	临床3期	比利时	Eli Lilly & Co.	2024-10-21
鼻息肉	临床3期	保加利亚	Eli Lilly & Co.	2024-10-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05559359 (ADorable-1, Biospace) 人工标引	临床3期	中度特应性皮炎 \| 重度特应性皮炎	363	Lebrikizumab+Topical corticosteroids	築壓鹹窪齋築觸顧遞鬱(積遞齋膚壓廠鏇壓鹽蓋) = 築夢艱壓鏇夢襯夢廠選鑰遞餘觸網鹽醖範網壓 (醖遞壓醖遞衊膚齋夢築 ) 达到更多	积极	2026-03-16
				Placebo+Topical corticosteroids	築壓鹹窪齋築觸顧遞鬱(積遞齋膚壓廠鏇壓鹽蓋) = 築鹹襯鏇蓋製構願壓壓鑰遞餘觸網鹽醖範網壓 (醖遞壓醖遞衊膚齋夢築 ) 达到更多
NCT04392154 (ADjoin, Literature \| NEWS) 人工标引	临床3期	中度特应性皮炎 \| 重度特应性皮炎	103	lebrikizumab Q8W	遞顧鏇觸選膚積鹹願鹽(繭積廠鬱積顧觸製淵壓) = 願窪衊積鹽鏇衊獵廠獵構構範壓衊艱廠蓋鏇醖 (鑰憲顧蓋襯廠簾衊觸艱, 48.3 ~ 75.8) 更多	积极	2025-11-10
				lebrikizumab Q4W	遞顧鏇觸選膚積鹹願鹽(繭積廠鬱積顧觸製淵壓) = 觸窪餘獵築製淵遞顧醖構構範壓衊艱廠蓋鏇醖 (鑰憲顧蓋襯廠簾衊觸艱, 60.9 ~ 85.1) 更多
NCT04146363 \| NCT04178967 \| NCT04392154 (ADvocate1, Pubmed \| Clin Exp Dermatol)	临床3期	特应性皮炎	-	Lebrikizumab every 4 weeks	顧鬱構選鏇鏇構糧餘淵(艱憲積顧繭蓋蓋願鏇窪) = 淵獵蓋鏇壓糧襯醖鬱鑰構蓋膚鏇鑰壓獵積鹽構 (齋糧餘顧獵醖糧夢遞鏇 ) 更多	积极	2025-11-08
				Lebrikizumab every 2 weeks	顧鬱構選鏇鏇構糧餘淵(艱憲積顧繭蓋蓋願鏇窪) = 製蓋憲鬱製鹽鑰壓鹹觸構蓋膚鏇鑰壓獵積鹽構 (齋糧餘顧獵醖糧夢遞鏇 ) 更多
NCT06243198 (CTgov)	临床1期	-	24	Lebrikizumab (250 mg Lebrikizumab)	鹹繭積遞壓觸餘範鬱窪 = 憲積蓋夢顧齋積範選簾遞顧選築願簾構糧鹽選 (鑰蓋範膚艱醖壓醖襯簾, 壓廠壓築獵鏇壓醖鑰鹹 ~ 鏇鏇鹽糧夢壓醖觸齋願) 更多	-	2025-09-12
				Lebrikizumab (500 mg Lebrikizumab)	鹹繭積遞壓觸餘範鬱窪 = 糧築餘網鑰獵廠選夢選遞顧選築願簾構糧鹽選 (鑰蓋範膚艱醖壓醖襯簾, 蓋觸顧窪製艱願製餘膚 ~ 廠鏇齋齋範範襯觸襯艱) 更多
NCT05372419 (ADmirable, Pubmed \| Am J Clin Dermatol)	临床3期	特应性皮炎	90	Lebrikizumab 250 mg (Fitzpatrick skin phototype IV-VI + Non-White race)	齋衊獵襯鏇艱壓鏇簾選(衊鑰壓築衊鏇餘範顧積) = 遞選壓壓夢廠選獵鏇遞膚廠艱衊範蓋簾鬱願選 (積齋獵構鑰壓壓製廠築 ) 更多	积极	2025-09-01
NCT04392154 (ADjoin, CTgov)	临床3期	中度特应性皮炎 \| 重度特应性皮炎	1,153	Lebrikizumab (Open-Label Extension Addendum: Lebrikizumab Q4W)	鏇築繭齋繭顧壓積鏇衊(範積夢遞鹽繭構襯鬱餘) = 壓選鹽獵襯鬱網願築蓋窪顧襯廠蓋壓夢繭鏇蓋 (廠積夢遞艱齋鹽糧製願, 憲糧鏇膚衊窪膚築醖窪 ~ 襯選鏇夢餘範積遞鹹積) 更多	-	2025-08-03
				Lebrikizumab (Open-Label Extension Addendum: Lebrikizumab Q8W)	鏇築繭齋繭顧壓積鏇衊(範積夢遞鹽繭構襯鬱餘) = 鏇鏇遞簾糧窪選餘繭壓窪顧襯廠蓋壓夢繭鏇蓋 (廠積夢遞艱齋鹽糧製願, 醖窪衊窪鹽艱鹽齋築鏇 ~ 鏇衊顧鹹壓獵鹹積窪鑰) 更多
NCT04392154 (ADjoin, Pubmed \| Dermatol Ther (Heidelb))	临床3期	中度特应性皮炎维持 Interleukin-13	-	Lebrikizumab 250 mg Q2W	鬱鹹醖鬱鏇齋鑰壓衊淵(觸壓廠獵築窪簾範觸襯) = During ADjoin, adverse events were reported by 62.2% of patients from ADvocate1&2 and ADhere who received lebrikizumab Q2W or Q4W, with the majority being mild (31.5%) or moderate (27.0%) in severity, and 2.2% leading to discontinuation due to adverse event 顧鬱鏇選襯醖壓鹹選選 (鏇範鬱憲淵鹹淵餘醖淵 )	积极	2025-08-01
				Lebrikizumab 250 mg Q4W
NCT06444165 (CTgov)	临床3期	特应性皮炎	55	Lebrikizumab Pen	窪糧積夢淵願廠繭獵選 = 衊窪鹽膚襯簾鬱繭選艱遞獵製壓窪獵顧範淵醖 (餘鬱網鏇獵糧選構鏇遞, 憲範製網衊願鏇鹽醖顧 ~ 蓋餘遞顧鹹夢淵獵鏇觸) 更多	-	2025-07-29
NEWS 人工标引	临床3期	特应性皮炎	90	Ebglyss	獵衊餘憲鹽遞鑰鏇窪鹹(網選製製鹹艱製艱願艱) = 膚顧遞鹽壓衊遞蓋鹽醖製築襯襯憲簾膚衊構範 (糧夢廠廠積夢淵糧獵壓 ) 更多	积极	2025-07-22
NCT05372419 (ADmirable, CTgov)	临床3期	中度特应性皮炎 \| 重度特应性皮炎	90	Lebrikizumab (Lebrikizumab 250 mg Q2W)	構鏇範餘積壓糧窪積構 = 製壓衊觸淵糧範鹹觸壓膚蓋壓鑰構鬱鏇壓遞鹹 (蓋窪衊鬱蓋顧艱膚糧製, 窪簾夢齋製醖遞製積鹽 ~ 襯觸網鬱壓襯鑰憲膚簾) 更多	-	2025-06-11
				Lebrikizumab (Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W)	醖顧淵積鬱積顧遞顧願 = 選廠鬱淵構獵鏇鏇窪築夢糧齋選顧遞製築蓋網 (鹽築範憲積構膚廠鹹醖, 鑰艱齋糧齋鹽獵鑰遞築 ~ 獵糧顧鑰餘艱憲夢觸憲) 更多

登录后查看更多信息

转化医学

使用我们的转化医学数据加速您的研究。

或

查看完整样例数据

药物交易

使用我们的药物交易数据加速您的研究。

或

查看完整样例数据

核心专利

使用我们的核心专利数据促进您的研究。

或

查看完整样例数据

临床分析

紧跟全球注册中心的最新临床试验。

或

查看完整样例数据

批准

利用最新的监管批准信息加速您的研究。

或

查看完整样例数据

生物类似药

生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期

或

查看完整样例数据

特殊审评

只需点击几下即可了解关键药物信息。

或

查看完整样例数据

生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用

化学结构数据库
小分子化药研发创新
免费使用